aetherAI vs Sectra Pathology
aetherAI's homepage describes the company's own analysis applications for slide quality control, cell counting and IHC quantification. A 2025 Translational Oncology paper with an aetherAI-affiliated author compared its Ki-67 morphometry against 3DHistech, Roche and manual counts. That suits a lab that wants analysis tools from the maker of its viewer.
Sectra sells image management and hosts AI made by others. The Digital Pathology Module holds K193054 from March 2020 and K232208 from April 2024, the latter for primary diagnosis with the Leica Aperio GT 450 DX and a specified Dell display in SVS and DICOM formats. Sectra says it was the first FDA clearance to allow DICOM pathology images for diagnosis. Through the Amplifier marketplace a lab buys third-party AI apps on a single contract, and the vendor claims 50-plus AI vendors integrated. A hospital that wants pathology and radiology images in one viewer fits Sectra, and a lab that wants to choose among many AI vendors finds aetherAI the weaker fit.
Pathology · Reviewed November 2, 2026
aetherAI
by aetherAI · founded 2015
FDA-cleared slide viewer for hospital pathology labs. Bone marrow and colon polyp AI modules are TFDA approved in Taiwan.
Sectra Pathology
by Sectra
Digital pathology image management (Sectra IDS7) with a marketplace for third-party AI apps. Sectra does not make the AI.
When to pick each one
aetherAI
- Own analysis apps from the viewer's maker
- Ki-67 paper by an affiliated author vs 3DHistech, Roche
Sectra Pathology
- Amplifier marketplace for third-party AI on one contract
- K232208 with DICOM support and Leica GT 450 DX
Score
Each row shows points earned of points available under the published rubric.
aetherAI
51of 100
Sectra Pathology
33of 100
| Dimension | aetherAI | Sectra Pathology | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 18 / 18 | 0 |
| HIPAA / SOC2 / BAA | 0 / 10 | 0 / 10 | 0 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 14.7 / 21 | 0 / 21 | +14.7 |
| RCT / meta-analysis / systematic review | 0 / 7.8 | 0 / 7.8 | 0 |
| Funding & adoption signal | 3 / 12 | 8.4 / 12 | -5.4 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 6 / 6 | 0 / 6 | +6 |
Scroll horizontally to see every column.
Pricing
aetherAI
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Sectra Pathology
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Contact form only. |
Evidence
aetherAI
FDA decisions
K233126 (opens in new tab)510(k)2024-05-30
aetherSlide
Peer-reviewed
2 PubMed records name aetherAI.
Sectra Pathology
FDA decisions
K232208 (opens in new tab)510(k)2024-04-16
Sectra Digital Pathology Module (Version 3.3)
K193054 (opens in new tab)510(k)2020-03-31
Sectra Digital Pathology Module
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | aetherAI | Sectra Pathology |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | 2015 | n/a |
| HQ | TW | SE |
Scroll horizontally to see both columns.
Common questions
Open the full pathology comparison
Digital pathology workflows with FDA-cleared cancer detection (prostate, breast, colon), IHC scoring (HER2, Ki67), and AI-powered image management. Tempus, PathAI, Proscia dominate.